Bambusa Therapeutics (BBTX) insider trading
Insider activity, historical context and SEC filings · data through Nov 2, 2026
Insiders put their own money in: $12.0M of open-market buys. See how similar setups did below.
Label: Net buying · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.Purchase Helmut Wolfgang Jeggle, Director bought 375,000 shares at $16.00 ($6.0M).
- Trade date
- Nov 2, 2026
- Disclosed to the SEC
- Nov 2, 2026
- Type
- Open-market purchase (code P)
Read the original SEC filing ↗All BBTX insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
Similar past setups: not applicable. There aren't enough comparable past cases for BBTX's latest buying to report odds. When insiders buy, this section shows how 16,899 similar past buys did over 90 days. How we calculate this →
Play with BBTX in the Research Lab
Pre-set to BBTX's latest insider buy of $10K or more (Nov 2, 2026: Helmut Wolfgang Jeggle, Salvia Investment Gmbh, $12.0M). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 16,899 past insider buys did.
Share price and insider trades
Price history unavailable.
Bambusa Therapeutics insider trading at a glance (Nov 2, 2026): in the past 12 months, 2 insiders bought $12.0M and 0 sold $0 of BBTX stock on the open market.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings · How we calculate this
BBTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | $12.0M | 2 | — | 0 |
Valuation, profit and volume
Valuation figures for BBTX are refreshed each weekday; some aren't published for every company. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 2 Bambusa Therapeutics, Inc. insiders reported open-market purchases totaling $12.0M, while 0 insiders reported sales totaling $0.
What happened after BBTX insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Nov 2, 2026 | Helmut Wolfgang JeggleDirector | $6.0M | pending | pending | pending |
| Nov 2, 2026 | Salvia Investment Gmbh10% Owner | $6.0M | pending | pending | pending |
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 2 NewSEC | Helmut Wolfgang JeggleDirector | Buy | 375,0009,264,301 held (+4%) | $16.00 | $6.0M | — | — |
| Nov 2 NewSEC | Salvia Investment Gmbh10% Owner | Buy | 375,0009,264,301 held (+4%) | $16.00 | $6.0M | — | — |
Insiders at Bambusa Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Helmut Wolfgang JeggleDirector | $6.0M | — | Nov 2, 2026 | — | — |
| Salvia Investment Gmbh10% Owner | $6.0M | — | Nov 2, 2026 | — | — |
BBTX stock: common questions
Are Bambusa Therapeutics, Inc. insiders buying BBTX stock?
In the past 12 months, 2 insiders reported open-market purchases of BBTX worth $12.0M. The latest was Director Helmut Wolfgang Jeggle bought $6.0M of BBTX at $16.00 — first open-market purchase in our records.
Are Bambusa Therapeutics, Inc. insiders selling BBTX stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.